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Abstract
Background: Development and deployment of an effective malaria vaccine would complement
existing malaria control measures. A blood stage malaria vaccine candidate, Merozoite Surface
Protein-3 (MSP3), produced as a long synthetic peptide, has been shown to be safe in non-immune
and semi-immune adults. A phase Ib dose-escalating study was conducted to assess the vaccine's
safety and immunogenicity in children aged 12 to 24 months in Korogwe, Tanzania
(ClinicalTrials.gov number: NCT00469651).
Methods: This was a double-blind, randomized, controlled, dose escalation phase Ib trial, in which
children were given one of two different doses of the MSP3 antigen (15 μg or 30 μg) or a control
vaccine (Engerix B). Children were randomly allocated either to the MSP3 candidate malaria
vaccine or the control vaccine administered at a schedule of 0, 1, and 2 months. Immunization with
lower and higher doses was staggered for safety reasons starting with the lower dose. The primary
endpoint was safety and reactogenicity within 28 days post-vaccination. Blood samples were
obtained at different time points to measure immunological responses. Results are presented up to
84 days post-vaccination.
Results: A total of 45 children were enrolled, 15 in each of the two MSP3 dose groups and 15 in
the Engerix B group. There were no important differences in reactogenicity between the two MSP3
groups and Engerix B. Grade 3 adverse events were infrequent; only five were detected throughout
the study, all of which were transient and resolved without sequelae. No serious adverse event
reported was considered to be related to MSP3 vaccine. Both MSP3 dose regimens elicited strong
cytophilic IgG responses (subclasses IgG1 and IgG3), the isotypes involved in the monocyte-
dependant mechanism of Plasmodium falciparum parasite-killing. The titers reached are similar to
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those from African adults having reached a state of premunition. Furthermore, vaccination induced
seroconversion in all vaccinees.
Conclusion: The MSP3 malaria vaccine candidate was safe, well tolerated and immunogenic in
children aged 12–24 months living in a malaria endemic community. Given the vaccine's safety and
its induction of cytophilic IgG responses, its efficacy against P. falciparum infection and disease needs
to be evaluated in Phase 2 studies.
Background
Falciparum malaria remains a global health problem,
accounting for 300–500 million clinical malaria episodes
and estimated 1–3 million deaths annually [1]. About
90% of the burden occurs in sub-Saharan Africa, espe-
cially in children below five years of age [2]. Current tools
to control malaria include use of insecticide-treated nets,
intermittent preventive treatment in pregnancy and
infants, and treatment on demand using effective anti-
malarial drugs. An effective malaria vaccine would be an
important complementary tool, whose development is
considered to be a high priority [3].
There are three main categories of malaria vaccine candi-
dates under research and development which target differ-
ent phases of the malaria parasite's life cycle, namely pre-
erythrocytic, blood stage and transmission blocking can-
didates[4]. It is well-established that malaria symptoms
are associated with the erythrocytic stage of the life cycle
and, therefore, the latter has attracted efforts to develop
vaccines either to prevent invasion or to ensure parasite
killing through antibody-triggered monocyte-mediators
[5].
Whereas most vaccine candidates have been identified by
experiments performed in experimental malaria models,
Merozoite Surface Protein 3 (MSP3) is a candidate identi-
fied by clinical studies in humans. The passive transfer of
protection by IgG from African adults into infected Thai
children identified the co-operation of IgG with blood
monocytes as the main defence mechanism in human
beings, in an antibody-dependent, cellular inhibitory
fashion (ADCI) [6]. Thereafter, the ADCI mechanism was
used to screen a genome-wide expression library and iden-
tified MSP3 as the main target of antibodies mediating the
monocyte-dependent Plasmodium falciparum killing effect
[7]. The monocyte-dependent mechanism implies that
only the cytophilic classes of IgG, namely IgG1 and IgG3,
can act in the ADCI mechanism and epidemiological
studies have confirmed that protection is associated with
such cytophilic responses against MSP3 [8-11].
In the process of research and development, MSP3 as a
long synthetic peptide, first underwent a Phase I trial in a
malaria-naïve population, which demonstrated that the
vaccine is safe and immunogenic, especially with alumin-
ium hydroxide adjuvant compared to montanide adju-
vant [12]. Moreover, antibodies elicited in volunteers
mediated a very strong monocyte-dependent parasite kill-
ing effect [13]. Therefore, MSP3, adjuvanted with alumin-
ium hydroxide, was further assessed in adults in a malaria
endemic community in Burkina Faso, where it was found
to be safe and able to elicit very significant immune
responses even in individuals with pre-existing immunity
[14].
This paper presents the results of a Phase Ib dose escala-
tion trial among Tanzanian children aged 12–24 months
that aim to assess the safety and immunogenicity of MSP3
adjuvanted by aluminium hydroxide when given at 0, one
and two months schedule.
Methods
Study design
The safety and immunogenicity of either a 15 μg or a 30
μg dose of MSP3 in aluminium hydroxide adjuvant versus
hepatitis B vaccine was assessed in a prospective double
blind, randomized, dose escalation trial in 12 to 24
months old children in Korogwe, Tanzania (ClinicalTri-
als.gov identifier NCT00469651). The trial was conducted
from November 2007 to November 2008. Ethical
approval was granted by the Tanzania Medical Research
Coordinating Committee (MRCC) and the ethical com-
mittee of the London School of Hygiene and Tropical
Medicine (LSHTM), and regulatory approval was granted
by the Tanzania Food and Drug Authority (TFDA). The
design, conduct and results of the trial were overseen by a
formally constituted data and safety monitoring board
(DSMB) operating under a charter, an independent local
safety monitor, and a clinical trial monitor. The study was
conducted in compliance with Helsinki Declaration
(1996 revision) and good clinical practice guidelines.
Study site
The study was conducted in a lowland village at Korogwe
District, north-eastern Tanzania. Korogwe District is
about 100 kilometers inland from Tanga. Briefly, it is a
tropical area with two rainy seasons: April to June and
October to December. While January and February are
normally dry, recently there have been climatic changes
such that there is no clear distinction of these seasons. The
estimated average entomological inoculation rate (EIR)
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ranged in the past from 30–100 infective bites per person
per year [15,16], however this has decreased markedly in
recent years. A demographic surveillance system funded
by African Malaria Network Trust (AMANET) was estab-
lished in the vaccination village in 2005. The study village
has no primary health facility and Korogwe District Hos-
pital, which is located 25 km away, serves the community.
In lowland villages of Korogwe, malaria is perennial with
peak seasons just after rain [15,17]. The lowland villages
were characterized by high transmission, but the recent
decline led to moderate transmission conditions (Lusingu
et al, manuscript in preparation). In Korogwe District
Hospital, malaria is the leading cause of admission and
deaths among under five children [18].
Participants
Healthy children by history and physical examination,
whose parents or guardians gave voluntary, signed informed
consent and were expected to be available for the whole
study period of 12 months, were eligible for recruitment and
enrolment if aged 12–24 months. The exclusion criteria
included symptoms and physical signs of disease that could
interfere with the interpretation of the trial results, or compr-
omize the health of the subjects, immunosuppressive ther-
apy (steroids, immune modulators or immune suppressors)
within three months prior to recruitment (for corticoster-
oids, this meant prednisone, or equivalent, ≥ 0.5 mg/kg/day)
and inability to be followed for any psychosocial or geo-
graphical reasons. Other criteria included laboratory abnor-
malities on screened blood samples, use of any
investigational drug or vaccine other than the study vaccine
within 30 days preceding the first dose of study vaccine, or
planned use up to 30 days after the third dose, suspected or
known hypersensitivity to any of the vaccine components or
to previous vaccine, planned administration of a vaccine not
foreseen by the study protocol within 30 days before the first
dose of vaccine, an exception being the receipt of an EPI or
licensed vaccine (measles, oral polio, Hepatitis B, meningo-
coccal and combined diphtheria/pertussis/tetanus vaccines),
which may be given 14 days or more before or after vaccina-
tion. Other exclusion criteria were evidence of chronic or
active hepatitis B infection, presence of chronic illness that,
in the judgement of the investigator, would interfere with the
study outcomes or pose a threat to the participant's health,
administration of immunoglobulin and/or any blood prod-
ucts within the three months preceding the first dose of study
vaccine or planned administration during the study period,
history of surgical splenectomy, and moderate or severe mal-
nutrition at screening defined as weight for age Z-score less
than -2.
Study vaccines
The investigational vaccine was MSP3 and the control vac-
cine was hepatitis B (Engerix B). The anti-malaria vaccine
MSP3 is a 96 amino-acids long synthetic peptide contain-
ing the amino-acid sequence 154–249 (3D7 clone). It is
lyophilized with a white amorphous powder appearance.
The vaccine is presented in multi-dose vials with the fol-
lowing formulation: active ingredient is MSP3 120 μg in
sodium chloride 9 mg/mL, trisodium-citrate (10 mM)
2.94 mg/mL and disodium-phosphate buffer (10 mM)
1.42 mg/mL as manufactured by Synprosis Ltd, France.
Before injection the vaccine is reconstituted in 0.9% saline
solution and then reconstituted vaccine was then mixed
with 1 mL of aluminium hydroxide, following the proce-
dure recommended by the manufacturer, Synprosis Ltd,
France. The minimum adsorption time of 60 minutes
before injection was respected. Following reconstitution
the vaccine was kept in a refrigerator between +2°C and
+8°C temperature and used within six hours.
The adsorbed vaccine was aliquoted into single-use
syringes, containing 15 μg or 30 μg of peptide. From one
multi-dose vial, individual vaccine doses of 0.5 mL were
prepared following a standard operating procedure (SOP)
provided by the manufacturer. The vaccine was adminis-
tered under sterile conditions, using a single-use syringe
for each subject and following a strict procedure of disin-
fection of the injection site. The vaccine was administered
subcutaneously.
Engerix B [Hepatitis B Vaccine (Recombinant)] is a non-
infectious recombinant hepatitis B vaccine developed and
manufactured by GlaxoSmithKline Biologicals. It con-
tains purified surface antigen of the virus obtained by cul-
turing genetically engineered Saccharomyces cerevisiae cells,
which carry the surface antigen gene of the hepatitis B
virus. The surface antigen expressed in S. cerevisiae cells is
purified by several physicochemical steps and formulated
as a suspension of the antigen adsorbed on aluminium
hydroxide. The procedures used to manufacture Engerix B
result in a product that contains no more than 5% yeast
protein. No substances of human origin are used in its
manufacture. Engerix B is supplied as a sterile suspension
for intramuscular administration. The vaccine is ready for
use without reconstitution and must only be shaken
before administration.
Study procedures
Site selection and sensitization
The study village was Kwashemshi village in Korogwe Dis-
trict, Tanga Region, Tanzania. The choice was based on
data from the demographic surveillance system (DSS)
according to which there were about 103 children
between 12–24 months in Kwashemshi village.
Sensitization meetings were held with village leaders,
elders and all villagers before beginning the study.
Screening and informed consent process
The flow of study participants during screening was based
on a standard operating procedure. Briefly, there were
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seven stations that included registration, information giv-
ing, consent signing, clinical assessment, photo taking,
blood draw and conclusion stations. Written informed
consent in Kiswahili was obtained from parents or guard-
ians during the screening visit. For those not able to write,
consent was documented by thumbprint, with counter
signature by a literate witness independent of the research
team.
Administration of vaccines and evaluation of clinical parameters
Eligible children were randomly assigned to receive three
doses of either MSP3 or Engerix B at intervals of 28 days.
MSP3 vaccination was staggered such that following
administration to the cohort receiving the 15 μg dose, a
six-day follow-up was performed, after which a report was
prepared and sent to Data Safety Monitoring Board
(DSMB). Vaccination of children with 30 μg of MSP3-LSP
only began once the DSMB had given written permission
to proceed. The study was double blind in that neither the
parents/guardians nor research team members involved
with vaccination or clinical observation were aware of the
vaccine allocation. Only staff responsible for preparing
the vaccines were aware of the vaccine allocations, but
these staff were not allowed any other role in the study.
Enrolled children were vaccinated by subcutaneous injec-
tion on days 0, 28 and 56. On each vaccination visit, chil-
dren were assessed clinically and 3–5 mls of venous blood
was collected for safety and immunogenicity parameters,
before administration of the study vaccines. Appropriate
medical treatment kit in case of an immediate anaphylac-
tic reaction following the administration of the vaccine
was always available during vaccine administration.
Immediate reactogenicity was observed for one hour fol-
lowing each vaccine dose. At all vaccination sessions, a
local safety monitor was available at the vaccination cen-
tre. Following each vaccination, all children were visited
at home by a field worker for six days to evaluate solicited
local symptoms (pain, swelling, induration, erythema
and pruritus at injection site); and solicited systemic reac-
tions, including fever (defined as axillary temperature ≥
37.5°C), drowsiness, loss of appetite and irritability/fuss-
iness (Table 1). Unsolicited adverse events occurring
within 28 days following each vaccination and serious
adverse events (SAE) occuring at any time during the trial
period (from first visit to last visit) were also documented.
Parents and guardians were encouraged to contact field
workers if their child was ill.
Measurement of biological parameters
Biological variables measured included haematological
[Hb (g/dl)], white blood cells [WBC (10,000/μl)], plate-
lets (1,000/μl), and biochemical [alanine aminotrans-
ferase ALT (IU/l), creatinine (μmol/l) and bilirubin (mol/
l)] parameters. Biochemical tests were run with serum or
plasma using a dry enzymatic detection system with a Vit-
ros DT60 II analyser (Orthoclinical Diagnostics, Johnson
and Johnson, Rochester, NY, USA). This system is based
on independent slides for each biochemical parameter
with all the necessary reagents for enzymatic reactions
incorporated. Three modules were used, chosen depend-
ing on the parameter to be analysed: DT60II Chemistry
System, DTE II Module and DTSC Module.
Haematological tests were conducted using a Sysmex KX-
21N cell counter (Kobe, Japan), which determines blood
parameters using total blood in EDTA. The KX-21N has
three detector blocks: the white blood cell (WBC) detector
block, the red blood cell (RBC) detector block and the
haemoglobin (Hb) detector block. The WBC detector
block counts leukocytes using the direct current resistance
(DCR) method (determining the changes of electric
impulses between two electrodes where the diluted sam-
ple is circulating). Erythrocyte and platelet counts are per-
formed in the RBC detector block, also by the DCR
method. The third block (HGB detector block) measures
the haemoglobin concentration using the no-cyanide Hb
method. All laboratory procedures adhered to good labo-
ratory practices following established standard opera-
tional procedures (SOPs).
Measurement of antibody responses
Anti-MSP3 specific antibodies (total IgG, IgM and of each
of the four IgG subclasses) were measured using indirect
enzyme-linked immunosorbent assay (ELISA) [19]. All
antigens tested were optimized and shown to be stable for
at least three weeks, when antigen-coated plates and
serum/plasma dilutions are refrigerated. The subclass spe-
cific reagents used were selected on the basis of low cross
reactivities among themselves, and ability to faithfully
react with African heavy chains dominant allotypes [19].
To control for inter-assay and day-to-day variations in the
standardized ELISA procedure, three-fold serial dilutions
of reference standard reagents (IgG, IgM and IgG1 to
IgG4) were directly coated onto each ELISA plate (Max-
isorp Nunc, Denmark) at a start concentration of 1,000
ng/ml (100 μl/well).
Optical density values for the test samples were converted
into antibody units with the standard reference curves
generated for each ELISA plate using a four parameter
curve-fit Microsoft Excel-based application. Samples were
re-tested if the coefficient of variation between duplicate
absorbance values were higher than 15% and plates were
also re-tested if the R-squared value of the standard curve
was less than 97%. The reference standards, PBS buffer
blank, positive and negative control plasma pools that
were included in each ELISA test plate allow for the deter-
mination of failed assay runs. The Afro-Immuno-Assay
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network ELISA procedure used in this study is described in
detail at the AMANET website http://www.amanet-
trust.org. Although all children received all three vaccine
doses as per protocol, the number of children whose
blood samples were available in sufficient amount to eval-
uate anti-MSP3 antibodies at day 84 were 15/15 in the 15
μg dose of MSP3, 12/15 in the 30 μg dose of MSP3 and
13/15 in Engerix B group. Results are shown below for
those individuals whose sera were available at day 84.
In order to compare immunogenicity data obtained in
African infants with previous immunizations performed
in European volunteers and immune responses following
exposure to high level of transmission, the sera of the 6
European volunteers immunized previously in Phase 1a
in Lausanne with 30 micrograms of MSP3 adjuvanted by
alum were tested in parallel with six randomly chosen sera
from the cohort followed in Korogwe (irrespective of the
dose of MSP3 received). The pool of 200 African adults
from a rural area of Ivory Coast that was employed in pas-
sive transfer in Thai subjects and 4 adults from the village
of Dielmo where malaria transmission is one of the high-
est in the world, with an average 250 infective bites per
person per year were used as positive controls[10]. Results
were expressed in AU as described in [19].
Data management
Participant information was captured on paper case report
forms (CRFs), which were double-entered into a Micro-
soft Access data base. The cleaned and validated database
was then analysed using STATA version10 http://
www.stata.com, based on a pre-defined analysis plan.
Safety and reactogenicity analyses included all rand-
omized children for whom any safety data were available,
and comprised descriptive statistics. The primary meas-
ures of safety and reactogenicity were the frequency of
local and systemic solicited adverse reactions for six days
after each dose and the frequency of unsolicited adverse
events, up to 28 days after each dose. The final descriptive
analysis was planned one month after dose 3 to evaluate
the safety and immunogenicity. The trial sample size was
determined on the primary evaluation criteria, concerning
Table 1: Severity grading of solicited adverse events
Adverse Event Intensity grade Parameter
Pain at injection site 0 Absent
1 Minor reaction to touch
2 Cries/protests on touch
3 Cries when limb is moved/spontaneously painful
Swelling at injection site Recorded greatest surface diameter in mm
0 None
1 < 5 mm
2 5 to 20 mm
3 > 20 mm
Induration at injection site Recorded greatest surface diameter in mm and graded as swelling above
Erythema at injection site Recorded greatest surface diameter in mm and graded as swelling above
Pruritus at injection site 0 Absent
1 Easily tolerated by the subject, causing minimal discomfort and not interfering with everyday 
activities.
2 Sufficiently discomforting to interfere with normal everyday activities.
3 Prevents normal, everyday activities.
Fever Recorded axillary temperature in °C
0 < 37.5°C
1 37.5 °C – 38.0°C
2 > 38°C – 39.0°C
3 > 39.0°C
Irritability/Fussiness 0 Behavior as usual
1 Crying more than usual/no effect on normal activity
2 Crying more than usual/interferes with normal activity
3 Crying that cannot be comforted/prevents normal activity
Drowsiness 0 Behavior as usual
1 Drowsiness easily tolerated
2 Drowsiness that interferes with normal activity
3 Drowsiness that prevents normal activity
Loss of appetite 0 Appetite as usual
1 Eating less than usual/no effect on normal activity
2 Eating less than usual/interferes with normal activity
3 Not eating at all
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the occurrence of systemic adverse events. The total sam-
ple size was calculated at 45 children to be distributed as:
15 to receive 15 μg MSP3 vaccine, 15 to receive 30 μg
MSP3 vaccine and 15 to receive Engerix B vaccine, allow-
ing for losses to follow-up or protocol deviations of not
more than 10%. With 14 children completing follow-up
in each MSP3 arm, the study would have 90% power to
detect at least one MSP3 vaccinated individual with a sys-
temic reaction (or a serious adverse event) if the underly-
ing risk of such an event was 15% or more. The trial would
have 80% power to detect at least one individual if the
underlying risk was 11% or more and 95% power to
detect at least one individual if the underlying risk was
19% or more. Immunogenicity focused primarily on anti-
body responses. Unblinding was done at Tanga Centre,
attended by the sponsor, inventor, LSM and the investigat-
ing team.
Results
Participant distribution and demographic data
A total of 45 children 12–24 months old were enrolled
and randomized, 15 to each treatment group (Figure 1).
All enrolled children were included in the safety popula-
tion since 100% (45/45) of children received all three vac-
cinations and all children completed the day 84 follow-up
visit. The median age of children was 1.4 years (minimum
1.0 year and maximum 2.0 years) with approximately
equal numbers of males and females.
Safety and reactogenicity
Both MSP3 vaccine doses and Engerix B vaccine formula-
tions were well tolerated. The incidence of local and sys-
temic solicited reactions is shown in Table 2 and Table 3,
respectively. The only major difference observed was for
induration among MSP3 vaccinated children compared
with Engerix B vaccinated children (Fisher's exact p-value
= 0.07). None of the grade three solicited symptoms were
classified as likely to be related to the vaccines.
There were five children who had serious adverse events
(SAEs) reported and one of these was classified as likely to
be related the control Engerix B vaccine. This was a febrile
episode that led to hospitalization a day after the first dose
of Engerix B, and whose aetiology remains unclear. Urine
analysis was normal. There were no signs of pneumonia
and no focal point of the fever was established. Malaria
parasites were not found in a blood smears. The child was
treated with antibiotics and antipyretics. The febrile epi-
sode resolved and the child was discharged within five
days, with no sequelae. The child received second and
third vaccination doses without further adverse events
detected. The other four children had SAEs that included
pneumonia and acute gastroenteritis. One of these chil-
MSP3 Phase 1 trial flow diagramFigure 1
MSP3 Phase 1 trial flow diagram.
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Table 2: Incidence of solicited local adverse events per vaccine type per dose
First dose Second dose Third dose
15 μg MSP3 30 μg MSP3 Engerix B 15 μg MSP3 30 μg MSP3 Engerix B 15 μg MSP3 30 μg MSP3 Engerix B
N = 15 N = 15 N = 15 N = 15 N = 15 N = 15 N = 15 N = 15 N = 15
Symptom Intensity n % n % n % n % n % n % n % n % n %
Any Overall 8 53 10 67 7 47 12 80 6 40 6 40 9 60 12 80 9 60
Grade 3 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
Pain Overall 3 20 2 13 1 6.7 1 6.7 1 6.7 1 6.7 0 0 1 6.7 2 13
Grade 3 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
Swelling Overall 3 20 7 47 5 33 4 27 1 6.7 1 6.7 3 20 2 13 3 20
Grade 3 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
Erythema Overall 0 0 2 13 1 6.7 1 6.7 1 6.7 1 6.7 1 6.7 0 0 2 13
Grade 3 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
Induration Overall 8 53 10 67 6 40 12 80 7 47 6 40 8 53 12 80 8 53
Grade 3 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
Pruritus Overall 0 0 0 0 0 0 0 0 0 0 1 6.7 0 0 0 0 0 0
Grade 3 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
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Table 3: Incidence of solicited systemic adverse events per vaccine type per dose
First dose Second dose Third dose
15 μg MSP3 30 μg MSP3 Engerix B 15 μg MSP3 30 μg MSP3 Engerix B 15 μg MSP3 30 μg MSP3 Engerix B
N = 15 N = 15 N = 15 N = 15 N = 15 N = 15 N = 15 N = 15 N = 15
Symptom Intensity n % n % n % n % n % n % n % n % n %
Any Overall 6 40 6 40 5 53 1 6.7 0 0 2 13 0 0 1 6.7 0 0
Grade 3 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
Related 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
Fever Overall 2 13 2 13 2 13 1 6.7 0 0 2 13 0 0 1 6.7 0 0
Grade 3 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
Related 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
Irritability Overall 2 13 0 0 2 13 0 0 0 0 0 0 0 0 0 0 0 0
Grade 3 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
Related 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
Drowsiness Overall 1 6.7 1 6.7 1 6.7 0 0 0 0 0 0 0 0 0 0 0 0
Grade 3 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
Related 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
Loss of 
appetite
Overall 5 33 5 33 0 0 0 0 0 0 0 0 0 0 0 0 0 0
Grade 3 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
Related 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
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Haematology and biochemical safety parametersFigure 2
Haematology and biochemical safety parameters. Line with filled squares show children vaccinated with 15 μg MSP3, 
filled circles show children vaccinated with 30 μg MSP3 and filled triangles show children vaccinated with Engerix B. Error bars 
show 95% confidence interval.
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dren was vaccinated with 30 μg MSP3, two of the children
were vaccinated with 15 μg MSP3, and one was vaccinated
with Engerix B. None of these events were deemed to be
causally-related to investigational or control vaccines.
At baseline, all children had haematological and bio-
chemical parameters within the normal ranges (Figure 2),
and this remained the case for all three vaccine groups
throughout the study period.
Immunogenicity
Anti-MSP3 antibodies were measured at baseline, 28 days,
56 days and 84 days. At baseline, before immunization all
children had very low levels of anti-MSP3 antibodies in
both the vaccine and control groups (Figure 3). Anti-
MSP3 total IgG increased after the second and the third
immunizations in both vaccinated groups, whereas no
major change was seen in the Engerix B controls. Similar
increases were observed in the 15 and the 30 μg dose
groups of MSP3. Isotype studies of the distribution of
anti-MSP3 cytophilic (IgG1+IgG3) versus noncytophilic
[IgG2+IgG4+IgM)] classes provided very clear-cut results.
Baseline values were similarly low among all children.
IgG1 antibodies showed a large increase in concentra-
tions, after the second and mostly after the third immuni-
zation, with no major difference between 15 or 30 μg of
MSP3. No such increase was observed in the control
group. The other cytophilic antibody class (IgG3) showed
a marked increase after the second dose in both MSP3
dose groups, although there was some indication of an
increase in the control group after the third dose. IgM con-
centrations increased moderately after the third immuni-
zation, by two-fold only, and as a similar increase was
seen among individuals receiving the control vaccine
EngerixB, the antigen-specificity of this result can be ques-
tioned (eg. this increase may be the result of a polyclonal
activation due to the adjuvant). The proportion of study
participants with an 8-fold increase in anti-MSP3 IgG sub-
classes at day 84 relative to their baseline status was the
highest for IgG1 and IgG3 antibodies at both MSP3 vac-
cine doses (Table 4). This almost exclusive dominance of
the cytophilic classes IgG1 and IgG3 is graphically
expressed by the high cytophilicity ratio shown in
Figure 4.
Results from comparative immuno-assays with European
Phase Ia volunteers sera, and adult sera from hyperen-
demic areas, show that only four of the six European vol-
unteers sero-converted, two being negative following
immunization and the remaining four having a mean titre
± SD of 6.12 ± 1.66, whereas all infants studied in Tanga
seroconverted and among the six included in the compar-
ative analysis, the mean titre + SD was of 10.68 ± 4.64
(Figure 3). This compares very well with the pool of Ivory
Coast adults which ELISA titre was of 11.48 and the mean
+ SD of four adults from the high transmission area of
Dielmo which titre was of 13.65 ± 3.63.
Discussion
The results indicate that MSP3 adjuvanted with alumin-
ium hydroxide is safe and has an acceptable reactogenicity
profile when administered according to 0, 1, 2-month
vaccination schedule to children aged 12–24 months in
Tanzania. This is consistent with other studies that have
also shown that MSP3 is safe in naïve and non-naïve
adults [12,14]. The reactogenicity of both doses of MSP3
appeared to be similar to Engerix B. Adverse events includ-
ing SAEs were infrequent and all resolved within few days
without sequelae. One SAE, which was likely related to
vaccination, occurred in the group that was vaccinated
with Engerix B. There was no significant difference in hae-
matology or biochemical parameters between vaccine
groups.
The design of this study had some inherent weakness for
evaluating reactogenicity. Thus the observed high inci-
dence of induration may be related to the fact that MSP3
was administered subcutaneously (SC), while the control
vaccine was given intramuscularly. The reason for choos-
ing the SC route was that the safety and immunogenicity
of the vaccine had been previously documented by this
route under Phase Ia, and Ib. Considerations should be
given to evaluating MSP3 via intramuscular route to be
consistent with the route generally used for other vaccines
in the expanded programme on immunization.
Some humoral immune responses to MSP3 were mark-
edly higher in both MSP3 dose groups as compared to
Engerix B vaccination. Most importantly all individuals
receiving the vaccine developed specific immune
responses and the antibodies produced were almost exclu-
sively in the two classes IgG1 and IgG3 which can bind Fcγ
Receptors and trigger the monocyte-dependant anti-para-
site killing effect [5]. Transmission intensity being rela-
tively low in this area of Tanzania, most children probably
had little or no previous exposure to malaria. Hence these
results show that a very simple formulation of MSP3 adju-
Table 4: Proportion of children with 8-fold increase of anti-MSP3 
antibodies at day 84 by vaccine type
Antibody 15 μg MSP3 30 μg MSP3 Engerix B
N n % N n % N n %
Total IgG 15 4 26.7 12 4 33.3 13 1 7.7
IgG1 15 15 100 12 10 83.3 13 2 15.4
IgG2 15 0 0 12 0 0 13 0 0
IgG3 15 13 86.7 12 11 91.7 13 6 46.2
IgG4 15 3 20 12 4 33.3 13 1 7.7
N = total vaccinated, n = responders
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Individual pattern of antibody responses to MSP3 by vaccination dose with respect to vaccine typeFigure 3
Individual pattern of antibody responses to MSP3 by vaccination dose with respect to vaccine type. Squares 
show children vaccinated with 15 μg MSP3, triangles show children vaccinated with 30 μg MSP3 and circles show children vac-
cinated with Engerix B. Lines connect median values. Abscissas: days post vaccination and ordinates: Elisa titers.
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vanted by alum, the adjuvant with the widest experience
and the most affordable, can induce in young African chil-
dren anti-MSP3 antibodies at high titers, predominantly if
not solely made of the IgG subclasses found most effective
in protecting against malaria [5,10,20]. Such an antibody
profile is just what is required. Further studies are on-
going to define the biological anti-parasite activity of
those antibodies under in-vitro conditions, although it is
clear that only Phase II can define their true protective
effects.
Comparative immunological results obtained in Korogwe
indicate very satisfactory immunogenicity with induction
of MSP3 specific antibodies in all children receiving the
vaccine. This is in contrast with results obtained previ-
ously at the 30 μg dose in European adult volunteers, not
all of whom seroconverted [5,10,20]. In addition, the
titres induced in young children were far higher than
those elicited in European volunteers and essentially sim-
ilar to those found in African adults exposed since birth to
continuous sporozoite challenge and multiple blood
stage infections. The children with limited prior exposure
to natural infection had baseline values before immuniza-
tion that were essentially similar to those of non-immune
Europeans. In other words, the MSP3 vaccine induced an
antibody response in 12 – 24 months old children similar
to that seen in adults exposed for more than 20 years to
the MSP3 protein presented by the parasite.
This was the first Phase 1 malaria vaccine trial to be per-
formed in Tanzania and some lessons were learnt during
the course of the trial. First, communities were well aware
and eager to participate in the process of development and
deployment of a malaria vaccine. This is to be expected
given that malaria is a leading cause of morbidity and
mortality in children, as well being responsible for eco-
nomic underdevelopment [21]. Second, the concept of
investigating the safety of a malaria vaccine is understood
with difficulty by the community. Strenuous efforts were
needed to explain the concept of safety. Third, the involve-
ment of African based sponsors (AMANET) for malaria
vaccines and the involvement of African researchers
(NIMR) in leading these malaria vaccine trials will
develop capacity of researchers from malaria endemic
regions in not only conducting vaccine trials but also
come up with strategies that will foster new ideas in con-
ducting successful clinical trials.
In conclusion, the results have confirmed that MSP3 is
safe and immunogenic in children and highlights the
need to conduct Phase 2 trials to evaluate the efficacy of
MSP3 in children living in malaria endemic communities.
Since 15 μg and 30 μg of MSP3 vaccine doses were simi-
larly well tolerated, it is reasonable to recommend that the
higher dose be taken forward for evaluation of efficacy.
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